Table 4

Effects of CPENSpm and chemotherapeutic drugs on MDA-MB-468 cellsa

DrugFractional growth inhibitionb
0.500.750.90
Concomitant CPENSpm+ drug
Doxorubicin1.28 ± 0.141.45 ± 0.191.73 ± 0.28
c-DDP0.96 ± 0.461.33 ± 0.601.75 ± 1.28
5-FU1.32 ± 0.441.81 ± 0.602.54 ± 0.97
Vinorelbine1.15 ± 0.021.10 ± 0.091.13 ± 0.16
Paclitaxel1.29 ± 0.221.37 ± 0.251.55 ± 0.33
Docetaxel1.171.391.72
Drug then CPENSpm
Doxorubicin1.331.271.25
c-DDP1.221.211.22
5-FU0.981.191.45
4HC0.90 ± 0.161.00 ± 0.321.15 ± 0.54
Vinorelbine0.93 ± 0.230.83 ± 0.180.78 ± 0.25
Paclitaxel0.86 ± 0.320.97 ± 0.071.36 ± 0.48
Docetaxel1.181.141.14
CPENSpm then CPENSpm and drug
Doxorubicin1.061.431.95
c-DDP1.35 ± 0.141.82 ± 0.102.56 ± 0.30
5-FU1.531.641.79
Vinorelbine0.98 ± 0.151.05 ± 0.101.20 ± 0.10
Paclitaxel1.17 ± 0.281.52 ± 0.452.71 ± 2.15
Docetaxel1.17 ± 0.261.38 ± 0.312.17 ± 1.24
  • a Results are shown for combination studies using the polyamine analog CPENSpm and drug with the MDA-MB-468 cell line at three different treatment schedules.

  • b CI values for fractional growth inhibitions of 0.50, 0.75, and 0.90 in the MDA-MB-468 cell line. Antagonism CI > 1.00; additivity CI = 1.00; synergy CI < 1.00 ± SD.